DOCSLIB.ORG

Maintenance Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Maintenance Drug List Commonly Prescribed Maintenance Medications Maintenance (or long-term) medications are those dosage form may be used to treat more than one drugs you may take on a regular basis to treat conditions medical condition. In these cases, each medication may such as high cholesterol, high blood pressure or diabetes. be classified according to its first U.S. Food and Drug Based on your benefit plan, you may get up to a 90-day Administration (FDA) approved use. Some strengths supply of covered maintenance medication delivered and/or formulations listed may not be covered. to you through a home delivery program or at select Please note that oral contraceptives are maintenance retail pharmacies. medications and are part of this list. However, this Some plans may require you to fill these prescriptions list does not include the trade names of all available through home delivery or at select retail pharmacies oral contraceptives because there are a large number in order to receive coverage. of products. Commonly used maintenance medications are listed in Coverage is always subject to the terms and limits of this guide. This list is not all-inclusive and may change your benefit plan. Please verify with your plan if there from time to time. are any additional requirements before a drug may be Most generic drugs listed are followed by a reference covered. For details about your plan, check your benefit brand drug in (parentheses). The brand name drug materials or call the number on your member ID card. in parentheses is listed for reference and may not be Third-party brand names are the property of their covered under your benefit. Some drugs in the same respective owners. ADHD/Stimulants Allergies GALANTAMINE HYDROBROMIDE - galantamine hydrobromide oral atomoxetine hcl cap 10 mg, 18 mg, ipratropium bromide nasal soln soln 4 mg/mL 25 mg, 40 mg, 60 mg, 80 mg, 0.03% (21 mcg/spray), 0.06% 100 mg (base equivalent) (42 mcg/spray) galantamine hydrobromide tab (Strattera) 4 mg (Razadyne) Alzheimer’s Disease clonidine hcl tab er 12hr 0.1 mg galantamine hydrobromide tab ARICEPT - donepezil hydrochloride (Kapvay) 8 mg, 12 mg tab 5 mg, 10 mg, 23 mg guanfacine hcl tab er 24hr 1 mg, memantine hcl cap er 24hr 7 mg, 2 mg, 3 mg, 4 mg donepezil hydrochloride orally 14 mg, 21 mg, 28 mg (base equivalent) (Intuniv) disintegrating tab 5 mg, 10 mg (Namenda xr) INTUNIV - guanfacine hcl tab er 24hr donepezil hydrochloride tab 5 mg, memantine hcl oral solution 1 mg, 2 mg, 3 mg, 4 mg 10 mg, 23 mg (Aricept) 2 mg/mL (base equivalent) EXELON - rivastigmine td patch 24hr memantine hcl tab 5 mg, 10 mg KAPVAY - clonidine hcl tab er 12hr 4.6 mg/24hr, 9.5 mg/24hr, (Namenda) 13.3 mg/24hr 0.1 mg NAMENDA - memantine hcl tab 5 mg, STRATTERA - atomoxetine hcl cap galantamine hydrobromide cap er 10 mg 24hr 8 mg, 16 mg, 24 mg 10 mg, 18 mg, 25 mg, 40 mg, NAMENDA XR - memantine hcl cap er (Razadyne er) 60 mg, 80 mg, 100 mg 24hr 7 mg, 14 mg, 21 mg, 28 mg (base equivalent) BRAND DRUGS generic drugs 1 Commonly Prescribed Maintenance Medications NAMZARIC - memantine hcl- nitroglycerin td patch 24hr propafenone hcl tab 150 mg, donepezil hcl cap er 24hr 7-10 mg, 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 225 mg, 300 mg 14-10 mg, 21-10 mg, 28-10 mg 0.6 mg/hr (Nitro-dur) propafenone hcl cap er 12hr 225 mg, RAZADYNE - galantamine PROCARDIA - nifedipine cap 10 mg 325 mg, 425 mg (Rythmol sr) hydrobromide tab 4 mg RANEXA - ranolazine tab er 12hr quinidine gluconate tab er 324 mg RAZADYNE ER - galantamine 500 mg, 1000 mg QUINIDINE SULFATE - quinidine hydrobromide cap er 24hr 8 mg, ranolazine tab er 12hr 500 mg, sulfate tab 200 mg, 300 mg 16 mg, 24 mg 1000 mg (Ranexa) RYTHMOL SR - propafenone hcl cap rivastigmine tartrate cap er 12hr 225 mg, 325 mg, 425 mg 1.5 mg, 3 mg, 4.5 mg, 6 mg Antiarrhythmics (base equivalent) amiodarone hcl tab 100 mg, sotalol hcl tab 80 mg, 120 mg, 160 mg (Betapace) rivastigmine td patch 24hr 200 mg, 400 mg 4.6 mg/24hr, 9.5 mg/24hr, BETAPACE - sotalol hcl tab 80 mg, sotalol hcl tab 240 mg 13.3 mg/24hr (Exelon) 120 mg, 160 mg sotalol hcl (afib/afl) tab 80 mg, 120 mg, 160 mg (Betapace af) Antiangina BETAPACE AF - sotalol hcl (afib/afl) tab 80 mg, 120 mg, 160 mg SOTYLIZE - sotalol hcl oral solution CARDIZEM - diltiazem hcl tab 30 mg, DIGOXIN - digoxin oral soln 5 mg/mL 60 mg, 120 mg 0.05 mg/mL TIKOSYN - dofetilide cap 125 mcg DILATRATE SR - isosorbide dinitrate (0.125 mg), 250 mcg (0.25 mg), cap er 40 mg digoxin oral soln 0.05 mg/mL (Digoxin) 500 mcg (0.5 mg) diltiazem hcl tab 30 mg, 60 mg, digoxin tab 125 mcg (0.125 mg), 120 mg (Cardizem) Anticoagulants/Antiplatelets 250 mcg (0.25 mg) (Lanoxin) AGGRENOX - aspirin-dipyridamole diltiazem hcl tab 90 mg disopyramide phosphate cap cap er 12hr 25-200 mg ISORDIL TITRADOSE - isosorbide 100 mg, 150 mg (Norpace) dinitrate tab 5 mg, 40 mg AGRYLIN - anagrelide hcl cap 0.5 mg dofetilide cap 125 mcg (0.125 mg), anagrelide hcl cap 0.5 mg (Agrylin) isosorbide dinitrate tab 5 mg, 250 mcg (0.25 mg), 500 mcg 40 mg (Isordil titradose) (0.5 mg) (Tikosyn) anagrelide hcl cap 1 mg isosorbide dinitrate tab 10 mg, flecainide acetate tab 50 mg, aspirin-dipyridamole cap er 12hr 20 mg, 30 mg 100 mg, 150 mg 25-200 mg (Aggrenox) isosorbide mononitrate tab 10 mg, LANOXIN - digoxin tab 62.5 mcg ASPIRIN/OMEPRAZOLE – aspirin- 20 mg (0.0625 mg), 125 mcg (0.125 mg), omeprazole tab delayed release 81-40 mg, 325-40 mg isosorbide mononitrate tab er 250 mcg (0.25 mg) 24hr 30 mg, 60 mg, 120 mg MEXILETINE HCL - mexiletine hcl cap BRILINTA - ticagrelor tab 60 mg, 90 mg nifedipine cap 10 mg (Procardia), 150 mg, 200 mg, 250 mg 20 mg MULTAQ - dronedarone hcl tab cilostazol tab 50 mg, 100 mg NITRO-BID - nitroglycerin oint 2% 400 mg (base equivalent) clopidogrel bisulfate tab 75 mg NITRO-DUR - nitroglycerin td patch NORPACE - disopyramide phosphate (base equivalent) (Plavix) 24hr 0.1 mg/hr, 0.2 mg/hr, 0.3 mg/hr, cap 100 mg, 150 mg dipyridamole tab 25 mg, 50 mg, 0.4 mg/hr, 0.6 mg/hr, 0.8 mg/hr NORPACE CR - disopyramide 75 mg NITRO-TIME – nitroglycerin cap er phosphate cap er 12hr 100 mg, DURLAZA - aspirin capsule er 24hr 2.5 mg, 6.5 mg, 9 mg 150 mg 162.5 mg BRAND DRUGS generic drugs 2 Commonly Prescribed Maintenance Medications EFFIENT - prasugrel hcl tab 5 mg, bupropion hcl tab er 24hr 150 mg, FETZIMA - levomilnacipran hcl cap er 10 mg (base equivalent) 300 mg (Wellbutrin xl) 24hr 20 mg, 40 mg, 80 mg, 120 mg ELIQUIS – apixaban tab 2.5 mg BUPROPION HYDROCHLORIDE ER - (base equivalent) PLAVIX - clopidogrel bisulfate tab bupropion hcl tab er 24hr 450 mg FLUOXETINE DR - fluoxetine hcl cap 75 mg (base equivalent) CAPLYTA – lumateperone tosylate delayed release 90 mg PRADAXA - dabigatran etexilate cap 42 mg FLUOXETINE HYDROCHLORIDE - mesylate cap 75 mg, 150 mg CELEXA - citalopram hydrobromide fluoxetine hcl tab 60 mg (etexilate base equivalent) tab 10 mg, 20 mg, 40 mg fluoxetine hcl (pmdd) tab 10 mg, prasugrel hcl tab 5 mg, 10 mg (base equivalent) 20 mg (Sarafem) (base equivalent) (Effient) citalopram hydrobromide oral fluoxetine hcl cap 10 mg, 20 mg, SAVAYSA - edoxaban tosylate tab soln 10 mg/5 mL 40 mg (Prozac) 15 mg, 30 mg, 60 mg citalopram hydrobromide tab fluoxetine hcl solution 20 mg/5 mL (base equivalent) 10 mg, 20 mg, 40 mg fluoxetine hcl tab 10 mg, 20 mg (base equivalent) (Celexa) XARELTO - rivaroxaban tab 2.5 mg, fluoxetine hcl tab 60 mg 15 mg, 20 mg CYMBALTA - duloxetine hcl enteric (Fluoxetine hcl) YOSPRALA - aspirin-omeprazole tab coated pellets cap 20 mg, 30 mg, 60 mg (base equivalent) fluvoxamine maleate tab 25 mg, delayed release 81-40 mg, 50 mg, 100 mg 325-40 mg DESVENLAFAXINE ER – desvenlafaxine tab er 24hr 50 mg, fluvoxamine maleate cap er 24hr ZONTIVITY - vorapaxar sulfate tab 100 mg, 150 mg 2.08 mg (base equivalent) 100 mg FORFIVO XL - bupropion hcl tab er desvenlafaxine succinate tab er 24hr 450 mg Arterial Disease 24hr 25 mg, 50 mg, 100 mg pentoxifylline tab er 400 mg (base equivalent) (Pristiq) GEODON - ziprasidone hcl cap 20 mg, 40 mg, 60 mg, 80 mg Behavioral Health DRIZALMA SPRINKLE – duloxetine hcl cap delayed release sprinkle INVEGA - paliperidone tab er 24hr ABILIFY - aripiprazole tab 2 mg, 5 mg, 20 mg, 30 mg, 40 mg, 60 mg 1.5 mg, 3 mg, 6 mg, 9 mg 10 mg, 15 mg, 20 mg, 30 mg (base equivalent) LATUDA - lurasidone hcl tab 20 mg, ABILIFY MYCITE - aripiprazole tab duloxetine hcl enteric coated 40 mg, 60 mg, 80 mg, 120 mg 2 mg with sensor, 5 mg with sensor, pellets cap 20 mg, 30 mg, 60 mg 10 mg with sensor, 15 mg with LEXAPRO - escitalopram oxalate tab (base equivalent) (Cymbalta) sensor, 20 mg with sensor, 30 mg 5 mg, 10 mg, 20 mg with sensor duloxetine hcl enteric coated (base equivalent) pellets cap 40 mg APLENZIN - bupropion hbr tab er LITHIUM CARBONATE - lithium (base equivalent) 24hr 174 mg, 348 mg, 522 mg carbonate cap 150 mg, 600 mg EFFEXOR XR - venlafaxine hcl cap er aripiprazole oral solution 1 mg/mL lithium carbonate cap 150 mg, 24hr 37.5 mg, 75 mg, 150 mg 600 mg (Lithium carbonate) aripiprazole orally disintegrating (base equivalent) tab 10 mg, 15 mg lithium carbonate cap 300 mg EMSAM - selegiline td patch 24hr 6 lithium carbonate tab 300 mg aripiprazole tab 2 mg, 5 mg, 10 mg, mg/24hr, 9 mg/24hr, 12 mg/24hr 15 mg, 20 mg, 30 mg (Abilify) lithium carbonate tab er 300 mg escitalopram oxalate soln 5 mg/ (Lithobid) bupropion hcl tab 75 mg, 100 mg 5 mL (base equivalent) lithium carbonate tab er 450 mg bupropion hcl tab er 12hr 100 mg, escitalopram oxalate tab 5 mg, 150 mg, 200 mg (Wellbutrin sr) 10 mg, 20 mg (base equivalent) LITHIUM - lithium oral solution (Lexapro) 8 meq/5 mL BRAND DRUGS generic drugs 3 Commonly Prescribed Maintenance Medications LITHOBID
Load more

Recommended publications
  • LGM-Pharma-Regulatory-1527671011
    Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide
    [Show full text]
  • Lifitegrast for the Treatment of Dry Eye Disease in Adults
    Expert Opinion on Pharmacotherapy ISSN: 1465-6566 (Print) 1744-7666 (Online) Journal homepage: http://www.tandfonline.com/loi/ieop20 Lifitegrast for the treatment of dry eye disease in adults Eric D. Donnenfeld, Henry D. Perry, Alanna S. Nattis & Eric D. Rosenberg To cite this article: Eric D. Donnenfeld, Henry D. Perry, Alanna S. Nattis & Eric D. Rosenberg (2017): Lifitegrast for the treatment of dry eye disease in adults, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2017.1372748 To link to this article: http://dx.doi.org/10.1080/14656566.2017.1372748 Accepted author version posted online: 25 Aug 2017. Published online: 04 Sep 2017. Submit your article to this journal Article views: 11 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ieop20 Download by: [108.6.184.233] Date: 04 September 2017, At: 04:29 EXPERT OPINION ON PHARMACOTHERAPY, 2017 https://doi.org/10.1080/14656566.2017.1372748 DRUG EVALUATION Lifitegrast for the treatment of dry eye disease in adults Eric D. Donnenfelda, Henry D. Perryb, Alanna S. Nattisb and Eric D. Rosenbergc aOphthalmic Consultants of Long Island, New York University Medical Center, Garden City, NY, USA; bOphthalmic Consultants of Long Island, Nassau University Medical Center, Rockville Centre, NY, USA; cWestchester Medical Center, Valhalla, NY, USA ABSTRACT ARTICLE HISTORY Introduction: Dry eye disease (DED) is a common ocular disorder that can have a substantial burden on Received 14 June 2017 quality of life and daily activities. Lifitegrast ophthalmic solution 5.0% is the first medication approved in Accepted 24 August 2017 the US for the treatment of the signs and symptoms of DED.
    [Show full text]
  • Summary of Appeals & Independent Review Organization
    All Other Appeals All other appeals are for drugs not in an inpatient hospital setting that Molina was not able to approve. Sometimes, the clinical information sent to us for these drugs do not meet medical necessity on initial review. When drug preauthorization requests are denied, a member or provider has the right to appeal. Appeals allow time to provide more clinical information. With complete clinical information, we can usually approve the drug. These are considered an appeal overturn. When the denial decision is not overturned, it is considered upheld. Service Code/Drug Name Service Code Description Number of Appeals Number of Appeals Total Appeals Upheld Overturned A9274 EXTERNAL AMB INSULIN DEL SYSTEM DISPOSABLE EA 0 1 1 Abatacept 3 1 4 Abemaciclib 1 0 1 Acalabrutinib 0 1 1 Acne Combination - Two Ingredient 1 0 1 Acyclovir 0 1 1 Adalimumab 7 14 21 Adrenergic Combination - Two Ingredient 1 0 1 Aflibercept 0 2 2 Agalsidase 1 0 1 Alfuzosin 1 0 1 Amantadine 1 0 1 Ambrisentan 0 1 1 Amphetamine 0 1 1 Amphetamine Mixtures - Two Ingredient 1 8 9 Apixaban 7 21 28 Apremilast 12 13 25 Aprepitant 0 1 1 Aripiprazole 5 9 14 ARNI-Angiotensin II Recept Antag Comb - Two Ingredient 6 9 15 Asenapine 0 1 1 Atomoxetine 1 3 4 Atorvastatin 0 1 1 Atovaquone 1 0 1 Axitinib 0 1 1 Azathioprine 0 1 1 Azilsartan 1 0 1 Azithromycin 1 0 1 Baclofen 0 1 1 Baricitinib 1 1 2 Belimumab 0 1 1 Benralizumab 1 0 1 Beta-blockers - Ophthalmic Combination - Two Ingredient 0 2 2 Bimatoprost 0 1 1 Botulinum Toxin 1 4 5 Buprenorphine 4 3 7 Calcifediol 1 0 1 Calcipotriene
    [Show full text]
  • Xiidra, INN-Lifitegrast
    EMA/334174/2020 Committee for Medicinal Products for Human Use (CHMP) Withdrawal assessment report Xiidra International non-proprietary name: lifitegrast Procedure No. EMEA/H/C/004653/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Classified as confidential by the European Medicines Agency Table of Contents 1. Joint Rapporteur’s Recommendations ..................................................... 5 2. Executive summary ................................................................................. 7 2.1. Problem statement ............................................................................................... 7 2.1.1. Disease or condition ........................................................................................... 7 2.1.2. Epidemiology and risk factors, screening tools/prevention ...................................... 7 2.1.3. Aetiology and pathogenesis ................................................................................ 7 2.1.4. Clinical presentation ........................................................................................... 8 2.1.5. Management ....................................................................................................
    [Show full text]
  • P&T Summary 1Q2021
    BLUE SHIELD OF CALIFORNIA FIRST QUARTER 2021 FORMULARY AND MEDICATION POLICY UPDATES EFFECTIVE MARCH 3, 2021 for Large Group, Small Group, and Individual & Family Plans The Blue Shield of California (BSC) Pharmacy and Therapeutics (P&T) Committee, consisting of network physicians and pharmacists, regularly evaluates drugs for formulary inclusion and medication policy coverage criteria. The first quarter 2021 P&T Committee decisions on formulary changes and medication policy changes, which apply to Commercial members with an outpatient drug benefit, are summarized below: PHARMACY BENEFIT FORMULARY UPDATE: Please refer to the appropriate drug formulary posted on our website for the following information: • Quantity limits, if applicable, for specific drugs • Formulary status of newly available strengths of existing drugs. Note: The formulary status of newly available strengths of existing drugs will have the same formulary status as the existing strengths unless otherwise noted. • Non-formulary and non-preferred generic drugs that do not require prior authorization or step therapy • Brand-name medications that are now non-formulary or non-preferred because these medications have newly available generic equivalents covered on the formulary Formularies are available at blueshieldca.com/pharmacy. Select the appropriate drug formulary – “Standard Drug Formulary”, “Value Drug Formulary”, or “Plus Drug Formulary”. Summary of changes to the Medicare formularies are available at blueshieldca.com/pharmacy. Select “Medicare Drug Formulary”, then
    [Show full text]
  • New Drug in Primary Care 2017 Lesinurad
    New Drug in Primary Care 2017 Lesinurad (Zurampic)® Ironwood ...................................................................................... 3 Pharmacology ................................................................................................................3 Pharmacokinetics ..........................................................................................................3 Clinical Trials .................................................................................................................3 Adverse Effects..............................................................................................................4 Do sing ............................................................................................................................4 Cost ...............................................................................................................................4 Lifitegrast (Xiidra®) Shire ..................................................................................................... 4 Pharmacology ................................................................................................................4 Pharmacokinetics ..........................................................................................................4 Clinical Trials .................................................................................................................5 Adverse Effects..............................................................................................................5
    [Show full text]
  • Abbvie Inc at Morgan Stanley Global Healthcare Conference
    MORGAN STANLEY HEALTHCARE CONFERENCE Bill Chase, Executive Vice President, Finance and CFO September 10, 2014 Disclaimer and Forward-Looking Statement NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION No Offer or Solicitation This document is provided for informational purposes only and does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this document in any jurisdiction in contravention of applicable law. Additional Information and Where to Find It In furtherance of the combination, AbbVie Private Limited (“New AbbVie”) has filed with the SEC a registration statement on Form S-4 containing a preliminary Proxy Statement of AbbVie that also constitutes a preliminary Prospectus of New AbbVie relating to the New AbbVie Shares to be issued to New AbbVie Stockholders in the combination. In addition, AbbVie, New AbbVie and Shire may file additional documents with the SEC. INVESTORS AND SECURITY HOLDERS OF ABBVIE AND SHIRE ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, AND OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION, CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Those documents, when filed, as well as AbbVie’s and New AbbVie’s other public filings with the SEC may be obtained without charge at the SEC’s website at www.sec.gov, at AbbVie’s website at www.abbvieinvestor.com and at Shire’s website at www.shire.com.
    [Show full text]
  • Quantity Limit Program Drug List
    Quantity Limit Program October 2021 The Quantity Limit Program encourages safe medication use. The chart below lists quantity limits for medications on Blue Cross Blue Shield of Michigan’s Clinical, Closed, Custom and Custom Select Drug Lists, Blue Cross and Blue Care Network’s Preferred Drug List and Blue Care Network’s Closed, Custom and Custom Select Drug Lists. The quantities are consistent with the Food and Drug Administration’s approved dosing guidelines. All opioids are limited to a 90 morphine milligram equivalent per day. Note: Some member limits may be slightly different. Please see your benefit information for your specific limits. Key SC = subcutaneous, mg = milligram, gm = gram, mcg = microgram, ml = milliliter, IU = international unit Not covered: You may be responsible for the full cost of the medication. Not applicable: Quantity limits may not apply. Sample Abilify MyCite = brand name (aripiprazole) = generic name Quantity limits for: BCBSM BCBSM BCBSM and BCN BCN BCN Medication Clinical, Custom, Closed Custom Select Preferred Custom, Closed Custom Select Drug Lists Drug List Drug List Drug Lists Drug List Abilify MyCite Not covered Not covered 1 tablet per day Not covered Not covered (aripiprazole) Absorica Not covered Not covered 5 capsules per day Not covered Not covered (isotretinoin) Absorica LD Not covered Not covered 5 capsules per day Not covered Not covered (isotretinoin) * Limited to a 15 day supply ** Limited to a 30 day supply Page 1 Revised: 10-01-21 Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.
    [Show full text]
  • Therapeutic Drug Class
    EFFECTIVE Version Department of Vermont Health Access Updated: 06/05/20 Pharmacy Benefit Management Program /2016 Vermont Preferred Drug List and Drugs Requiring Prior Authorization (includes clinical criteria) The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include: "A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives" From Act 127 passed in 2002 The following pages contain: • The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories. • The therapeutic classes of drugs which have clinical criteria for Prior Authorization may or may not be subject to a preferred agent. • Within both categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters. Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non- preferred agents have been included and are listed in the right-hand column. Any drug not listed as preferred in any of the included categories requires Prior Authorization. Approval of non-preferred brand name products may require trial and failure of at least 2 different generic manufacturers. GHS/Change Healthcare Change Healthcare GHS/Change Healthcare Sr. Account Manager: PRESCRIBER Call Center: PHARMACY Call Center: Michael Ouellette, RPh PA Requests PA Requests Tel: 802-922-9614 Tel: 1-844-679-5363; Fax: 1-844-679-5366 Tel: 1-844-679-5362 Fax: Note: Fax requests are responded to within 24 hrs.
    [Show full text]
  • Disclosures Pharmacist Objectives Technician Objectives New Drug
    8/31/2016 Disclosures • Both presenters have nothing to disclose. New Drug Updates Lalita Prasad‐Reddy, PharmD, MS, BCACP, BCPS, CDE Clinical Assistant Professor Chicago State University College of Pharmacy Diana Isaacs, PharmD, BCPS, BC‐ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center September 16, 2016 Pharmacist Objectives Technician Objectives • Describe the place in therapy and mechanisms of action • Describe the place in therapy and mechanisms of of newly approved drugs in the last 15 months. action of newly approved drugs in the last 15 months. • Compare newly approved agents from current agents utilized in the management of disease. • Compare newly approved agents from current agents utilized in the management of disease. • Describe newly approved agents in terms of their place in therapy, effectiveness, safety, and patient administration. • Describe newly approved agents in terms of their place in therapy, effectiveness, safety, and patient administration. • Summarize important patient counseling pearls for newly approved agents for the management of disease. New Drug Stats New Drugs & Disease States • From 2006‐2014 • Diabetes • Heart Failure – – – Average 28 novel drugs approved/year Insulin degludec (Tresiba®) Sacubitril/valsartan (Entresto®) – Lixisenatide (Adlyxin®) – Ivabradine (Corlanor®) • In 2015, 45 novel drugs approved • Gout • Asthma – 16 (36%) are first‐in‐class (ex. Praxbind®) – Lesinurad (Zurampic®) – Reslizumab (Cinqair®) – 21 (47%) to treat rare/orphan diseases (ex. Kanuma®) – Mepolizumab (Nucala®) – 29 (64%) approved in the US before other countries (ex. • Bleeding reversal Entresto®) – Idarucizumab (Praxbind®) • Hepatitis C – Sofosbuvir/velpatasvir (Epclusa®) • Hyperlipidemia • In 2016 (as of July) – Elbasvir/grazoprevir (Zepatier®) – Evolocumab (Repatha®) – Daclatasvir (Daklinza®) – 16 novel drugs approved – Alirocumab (Praluent®) Novel Drugs Summary 2015.
    [Show full text]
  • HMSA Provider Update Healthpro News
    HealthPro News A monthly publication for participating HMSA health care providers, facilities, and their staff. October 2016 ADMINISTRATION & NEWS C Q M Open Enrollment Season Open enrollment is here! HMSA has resources to help your patients learn more about the open enrollment What’s season. These resources include posters to display in your office and rack cards to Inside give your patients or have available at your reception counter. The open enrollment periods for our members include: Coding & Claims • QUEST Integration: October 1–31. 4 • EUTF retirees: October 10–31. Pharmacy • HMSA Akamai Advantage®: October 15–December 7. 4 • Affordable Care Act (ACA), individuals and small groups: November 1–January 31. Plans 11 • Federal Plan 87: November 14–December 12. To get these open enrollment resources, email Provider Services at Policy News [email protected] or call 948-6820 on Oahu or 1 (877) 304-4672 11 toll-free on the Neighbor Islands. Calendar 13 C Q M Bone Density Scans HMSA is offering a new service for HMSA Akamai Advantage members who need evaluation for osteoporosis. Members who have had a recent fracture and have difficulty going to an imaging center for a DXA scan can have a heel scan provided by our Health Management staff at an HMSA Center or in their home. HMSA will contact physicians to offer this service as we identify members who are eligible. Heel scans are free for eligible members; HMSA will handle scheduling and testing and will send the results to your office. C Q M Commercial QUEST Medicare C Q M Integration 2016 High Performer Program HMSA is pleased to offer a special bonus program to our primary care providers again this year.
    [Show full text]
  • National Drug List
    National Drug List Drug list — Four Tier Drug Plan Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA). The following is a list of plan names to which this formulary may apply. Additional plans may be applicable. If you are a current Anthem member with questions about your pharmacy benefits, we're here to help. Just call us at the Pharmacy Member Services number on your ID card. Solution PPO 1500/15/20 $5/$15/$50/$65/30% to $250 after deductible Solution PPO 2000/20/20 $5/$20/$30/$50/30% to $250 Solution PPO 2500/25/20 $5/$20/$40/$60/30% to $250 Solution PPO 3500/30/30 $5/$20/$40/$60/30% to $250 Rx ded $150 Solution PPO 4500/30/30 $5/$20/$40/$75/30% to $250 Solution PPO 5500/30/30 $5/$20/$40/$75/30% to $250 Rx ded $250 $5/$15/$25/$45/30% to $250 $5/$20/$50/$65/30% to $250 Rx ded $500 $5/$15/$30/$50/30% to $250 $5/$20/$50/$70/30% to $250 $5/$15/$40/$60/30% to $250 $5/$20/$50/$70/30% to $250 after deductible Here are a few things to remember: o You can view and search our current drug lists when you visit anthem.com/ca and choose Prescription Benefits. Please note: The formulary is subject to change and all previous versions of the formulary are no longer in effect.
    [Show full text]